Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 31, 2014
- Accepted in final form November 20, 2014
- First Published March 18, 2015.
Article Versions
- Previous version (March 18, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- V. Shane Pankratz, PhD,
- Rosebud O. Roberts, MBChB,
- Michelle M. Mielke, PhD,
- David S. Knopman, MD,
- Clifford R. Jack Jr, MD,
- Yonas E. Geda, MD,
- Walter A. Rocca, MD, MPH and
- Ronald C. Petersen, MD, PhD
- V. Shane Pankratz, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIA, P50 AG16574, Data Core Director, 2004-present (2) NIA, U01 AG06786, Co-Investigator, 2005-present (3) NIA, R01 AG32990, Co-Investigator, 2009-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rosebud O. Roberts, MBChB,
NONE
NONE
NONE
Journal of Alzheimer's Disease; Associate Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH U01 AG006786 [Coinvestigator] 2009-2014
NONE
Mayo Clinic [coinvestigator], Driskill Foundation, and GHR Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Michelle M. Mielke, PhD,
NONE
NONE
I have received speaker honoraria from Eli Lilly and AbbVie.
Alzheimer's and Dementia: The Journal of the Alzheimer Association, associate editor, 2012-present Journal of Alzheimer Disease, associate editor, 2012-present
NONE
NONE
NONE
Eli Lilly and AbbVie
NONE
NONE
NONE
NONE
Dr. Mielke was funded by the following NIH grants: U01 AG037526 U01 AG006786
NONE
Dr. Mielke also received research support from the Walter S. and Lucienne B. Driskill Foundation which started in May 2012-present. Alzheimer drug discovery foundation. Role:PI. Date: 03/01/2013-present Michael J. Fox Foundation. Role: PI. Date: 01/01/2014-06/30/2015.
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Knopman, MD,
Consultant Bluefield project (frontotemporal demantia); Lundbeck Pharmaceuticals (Sept 2013 ongoing); DIAN study DSMB (Sept 2013 ongoing).
NONE
(1) Lecture, University of Pennsylvania, January 2013 (2) Lecture, St Johns Hospital, Jackson Hole Wyoming June 2013 (3) Lecture, Amer Soc Neuroradiol, San Diego CA, May 2013 (4) Lectures, Alzheimer Conference, Seoul Korea, December 2014
Neurology, Deputy Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Tau Rx clinical trial
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer?s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clifford R. Jack Jr, MD,
scientific advisory panels: Janssen and Eli Lily
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health: RO1 AG011378 PI; U01 AG024904-01 co-I; RO1 AG37551 co-I; 1U01HL096917 co-I; U01 AG032438 co-I; RO1 AG041851-01 co- PI
NONE
NONE
own stock in Johnson and Johnson
NONE
NONE
NONE
Johnson and Johnson
NONE
- Yonas E. Geda, MD,
NONE
NONE
NONE
2013 to present : Member, editorial board of International Psychogeriatrics.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health (NIH), K01 MH068531
NONE
1-Harold Amos Medical Faculty Development Award (RWJ foundation). 2- European Union Regional Development Fund (CZ.1.05/1.1.00/02.0123)
NONE
NONE
NONE
NONE
NONE
NONE
- Walter A. Rocca, MD, MPH and
NONE
NONE
NONE
2008 - to present: Revista de Neurologia (in Spanish) 2008 - to present: Clinical Epidemiology & Risk Management 2008 - to present: Maturitas 2009 - to present: Menopause Dr. Rocca is a member of the editorial boards of the above-listed journals. No compensation is received from any of these journals for his participation.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Rocca receives research support from the NIH (R01 AG034676 [PI]; U01 AG006786 [coinvestigator]), and from the NIH P50 AG044170[coinvestigator].)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronald C. Petersen, MD, PhD
(1) Pfizer, Inc., Chair, Data Monitoring Committee; (2) Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee
NONE
NONE
NONE
NONE
Mild Cognitive Impairment,Oxford University Press, 2003
NONE
(1) Roche Incorporated, (2) Merck, (3) Genentech
NONE
NONE
NONE
NONE
National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) R01-AG011378 (Co-I) U01-AG024904 (Co-I) Non-financial disclosures: National Advisory Council on Aging, National Institute on Aging
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Internal Medicine (V.S.P.), University of New Mexico Health Sciences Center, Albuquerque; Division of Epidemiology, Department of Health Sciences Research (R.O.R., M.M.M., W.A.R., R.C.P.), and Departments of Neurology (R.O.R., M.M.M., D.S.K., R.C.P.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and the Departments of Psychiatry, Psychology, and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.
- Correspondence to Dr. Petersen: peter8{at}mayo.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Quantity and quality of mental activities and the risk of incident mild cognitive impairmentJanina Krell-Roesch, Jeremy A. Syrjanen, Maria Vassilaki et al.Neurology, July 10, 2019 -
Article
Subjective cognitive decline and risk of MCIThe Mayo Clinic Study of AgingArgonde C. van Harten, Michelle M. Mielke, Dana M. Swenson-Dravis et al.Neurology, June 29, 2018 -
Article
Higher risk of progression to dementia in mild cognitive impairment cases who revert to normalRosebud O. Roberts, David S. Knopman, Michelle M. Mielke et al.Neurology, December 18, 2013 -
Articles
The incidence of MCI differs by subtype and is higher in menThe Mayo Clinic Study of AgingR.O. Roberts, Y.E. Geda, D.S. Knopman et al.Neurology, January 25, 2012